EUVIMEDEUVIMED entdecken
Crossref

Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer

Joseph A Dottino, Katharine M Esselen, Rebecca Costa, Stephanie Argetsinger, Mahnum Shahzad, Dennis Ross-Degnan, Anita K Wagner

Value in Health · 2024

DOI: 10.1016/j.jval.2024.05.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2024. Verfasst von Joseph A Dottino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: jdottino@bidmc.harvard.edu. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Ovarian Neoplasms, Health Expenditures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: We sought to quantify exposure to and financial impacts of poly (adenosine diphosphate ribose) polymerase inhibitor (PARPi) treatments for eventually withdrawn ovarian cancer indications. METHODS: We identified in Optum's deidentified Clinformatics® Data Mart database 1695 patients with ovarian cancer diagnoses who received olaparib, rucaparib, or niraparib between January 2015 and September 2021. We describe PARPi use and out-of-pocket, total healthcare, and PARPi spending among patients with ovarian cancer with 3 or more previous lines of therapy. RESULTS: Of the 1695 patients who received PARPi, 254 were estimated to have been heavily pretreated and exposed to eventually withdrawn indications. Cumulative total medical and pharmacy costs for these patients were $53 392 184; PARPi costs accounted for 34%. Median PARPi cost per patient was $43 347. Cumulative out-of-pocket costs totaled $533 281. CONCLUSIONS: Potential patient harm, including financial toxicity, might have been mitigated through more stringent drug approval requirements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsOvarian NeoplasmsHealth ExpendituresHumansFemaleMiddle AgedAgedPiperidinesIndazolesPhthalazinesIndolesPiperazines

Stichwörter der Autor:innen

drug regulationdrug spendingindication withdrawaloncologyovarian cancer

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPiperidinesrucaparibniraparibIndazolesPhthalazinesIndolesolaparibPiperazines

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: jdottino@bidmc.harvard.edu.
  • Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.

Förderung

  • American Cancer Society

Zitieren

APA

Dottino, J. A., Esselen, K. M., Costa, R., Argetsinger, S., Shahzad, M., Ross-Degnan, D., & Wagner, A. K. (2024). Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer. Value in Health. https://doi.org/10.1016/j.jval.2024.05.022

Vancouver

Dottino JA, Esselen KM, Costa R, Argetsinger S, Shahzad M, Ross-Degnan D, et al. Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer. Value in Health. 2024. doi:10.1016/j.jval.2024.05.022

BibTeX
@article{Dottino2024,
  author = {Dottino, Joseph A and Esselen, Katharine M and Costa, Rebecca and Argetsinger, Stephanie and Shahzad, Mahnum and Ross-Degnan, Dennis and Wagner, Anita K},
  title = {Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer},
  journal = {Value in Health},
  year = {2024},
  doi = {10.1016/j.jval.2024.05.022}
}
Kostenlos starten →